The global NASH market is surging, driven by rising obesity, diabetes, and innovative therapies like Resmetirom. Non-invasive diagnostics and robust pipelines fuel growth, with North America leading. More Info: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market